- Home
- AVBP vs ADPT Comparison
AVBP vs ADPT Comparison
Compare AVBP & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- ADPT
- Stock Information
- Founded
- AVBP 2021
- ADPT 2009
- Country
- AVBP United States
- ADPT United States
- Employees
- AVBP N/A
- ADPT N/A
- Industry
- AVBP
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVBP
- ADPT Health Care
- Exchange
- AVBP NYSE
- ADPT Nasdaq
- Market Cap
- AVBP 980.3M
- ADPT 1.2B
- IPO Year
- AVBP 2024
- ADPT 2019
- Fundamental
- Price
- AVBP $27.81
- ADPT $7.32
- Analyst Decision
- AVBP Strong Buy
- ADPT Buy
- Analyst Count
- AVBP 5
- ADPT 4
- Target Price
- AVBP $37.40
- ADPT $7.38
- AVG Volume (30 Days)
- AVBP 140.3K
- ADPT 1.5M
- Earning Date
- AVBP 02-10-2025
- ADPT 02-11-2025
- Dividend Yield
- AVBP N/A
- ADPT N/A
- EPS Growth
- AVBP N/A
- ADPT N/A
- EPS
- AVBP N/A
- ADPT N/A
- Revenue
- AVBP N/A
- ADPT $177,282,000.00
- Revenue This Year
- AVBP N/A
- ADPT $6.48
- Revenue Next Year
- AVBP N/A
- ADPT $18.72
- P/E Ratio
- AVBP N/A
- ADPT N/A
- Revenue Growth
- AVBP N/A
- ADPT N/A
- 52 Week Low
- AVBP $14.35
- ADPT $2.28
- 52 Week High
- AVBP $36.37
- ADPT $8.33
- Technical
- Relative Strength Index (RSI)
- AVBP 53.46
- ADPT 58.53
- Support Level
- AVBP $25.90
- ADPT $5.98
- Resistance Level
- AVBP $29.71
- ADPT $8.24
- Average True Range (ATR)
- AVBP 1.49
- ADPT 0.60
- MACD
- AVBP 0.25
- ADPT 0.01
- Stochastic Oscillator
- AVBP 67.85
- ADPT 73.25
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).